Why Celgene ' s Acquisition Of Juno Matters For Biotech And Investors

Celgene just acquired immunotherapy biotech Juno Therapeutics in a $9 billion dollar deal. The deal will allow Celgene to compete in a space already occupied by Novartis and Gilead as they vie for hegemony in a new field of oncology. Learn why this deal is important to the biotech sector.

Source: Forbes.com Healthcare News - January 23, 2018 Category: Pharmaceuticals Authors: Steve Brozak, Contributor Tags: NASDAQ:CELG NASDAQ:JUNO NYSE:BMY NYSE:NVS Source Type: news